32 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
7 May 24
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
7:39am
to defend our intellectual property; the impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply … chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those in this “Risk
8-K
EX-99.1
pux3a6npqk3zxhd9twi
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
7q96qy aai37ic8
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
9403q5yd edy9
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
b7zt h0l8phlq
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
8w0ji01e rff
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.2
o8z0f4s6pgpb
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
bm106e i3gm
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
rewgn
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
psbc9i0ec210ll3 419n
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-99.1
53jwbiz
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
EX-99.1
2na07hkeklb0k
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
92misxrkfmpg6q 1a
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
0kycnligpgvm ed
20 Oct 22
Draft registration statement
12:00am
8-K
EX-99.1
bextb4mix iy
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am